

오스코텍

주주 소통 간담회

November 26, 2025

Translating Science into Medicine

 | Oscotec Inc.

오스코텍 R&D 회사의 성과 및 미래 Pipeline


향후 1~2년마다 1개 L/O 목표

	기전/차별성	질병	Discovery	Lead Opt	Preclinical	Phase I	Phase II	
ADEL-Y01	- 타우 표적, 안전성 입증 - 차세대 항체 치료제	치매						단기 L/O
OCT-598	- 내성 핵심 경로 차단 EP2/4 이중 저해 - 내성항암제	고형암						
GCN-3545	- Geno-K 플랫폼 활용 - BIC ROCK2 억제제	폐섬유증						
OCT-648	- 섬유화 차단 - NUAK1 표적 억제제	만성신장질환						중기 L/O ('27 Q1~)
ONC1	- 내성 핵심 경로 차단 NUAK1/2 이중저해 - 내성항암제	고형암						
ONC2 ~ 5	신규 Modality, 혁신 플랫폼 등 공동개발	고형암						장기 Pipeline
DAC1 ~ 3	- 암세포 특이 효소 기반 - 안정성 강화 - 차세대 DAC 치료제	고형암						


* 상용화 파이프라인: 렉라자 (폐암), 내성 차단 기전을 갖춘 차세대 EGFR kinase 억제제

* 기타 Pipeline(추가 비용 투입 없이 기술이전): Cevidoplenib, 자가면역질환제(임상2상 완료), '26 Q4 L/O / Denfivontinib, 표적치료제(임상1상 완료), '26 Q2 L/O

R&D 로드맵 2020-2030



렉라자 이후의 오스코텍 내성항암제 전략



- 오스코텍 내성항암제 플랫폼
- 표적/물질 데이터베이스
- 내성 발달 기전 원천 억제
- 상용 약물 병용 전략
- 약물 안전성 - 신규 질환 분야 적용

Cevidoplenib

- History
 - One of the most advanced SYK-selective inhibitors worldwide (solvleplenib, BI-894416)
 - Proven competitive efficacy and superior tolerability in chronic ITP patients (2nd line) in global P2 study
- Current status
 - Initiated an investigator-initiated P2 study in newly diagnosed ITP patients (1st line)
 - Developed new crystal forms and formulation; patent application filed
 - High quality drug products manufactured; bioequivalence study planned
- Prospect
 - To explore new indications to maximize the potential value via partnering and external investment

The image displays two screenshots of the FIERCE Biotech website. The top screenshot features a headline: "Sanofi signs €545M deal to explore Formation's JAK/SYK inhibitor in new indication", attributed to James Waldron and dated June 23, 2025. The bottom screenshot shows another headline: "Ignota buys Kronos' pipeline, igniting 2nd chance salvo to rescue shelved programs", attributed to Nick Paul Taylor and dated October 6, 2025. Below these, a snippet of a research article is visible, titled "Syk inhibitor attenuates lupus in FcγRIIb^{-/-} mice through the Inhibition of DNA extracellular traps from macrophages and neutrophils via p38MAPK-dependent pathway", published on February 17, 2025, in the journal Cell Death Discovery.

FIERCE Biotech | Biotech | Research | Medtech | CRO | Special Reports | Trending | Fierce 50 | Awards

BIOTECH

Sanofi signs €545M deal to explore Formation's JAK/SYK inhibitor in new indication

By James Waldron · Jun 23, 2025 9:47am

FIERCE Biotech | Biotech | Research | Medtech | CRO | Special Reports | Trending | Fierce 50 | Awards

BIOTECH

Ignota buys Kronos' pipeline, igniting 2nd chance salvo to rescue shelved programs

By Nick Paul Taylor · Oct 6, 2025 5:45am

Article | [Open access](#) | Published: 17 February 2025

Syk inhibitor attenuates lupus in FcγRIIb^{-/-} mice through the Inhibition of DNA extracellular traps from macrophages and neutrophils via p38MAPK-dependent pathway

[Kritsanawan Sae-khow](#), [Awirut Charoensappakit](#), [Kanyarat Udompornpitak](#), [Wilasinee Saisorn](#), [Jiraphorn Issara-Amphorn](#), [Tanapat Palaga](#) & [Asada Leelahavanichkul](#) ✉

[Cell Death Discovery](#) 11, Article number: 63 (2025) | [Cite this article](#)

Confidential


Denfivontinib

- History

- A potent FLT3/AXL dual inhibitor
- Completed P1a as an injectable in AML patients in the US; confirmed efficacy in the subjects with FLT3-mutation
- Strategic decision to halt further development in AML due to the lack of differentiation vs Xospata® (gilteritinib, Astellas)
- Completed P1a as an oral pill in solid tumors in Korea; confirmed good exposure (PK) and safety
- Strategic decision to deprioritize as OCT-598 advances

- Prospect

- Potential collaboration/option deal on developing companion diagnostics for AML



Carter et al., Signal Transduction and Targeted Therapy, 2020

Confidential

ADEL-Y01

- History


- Acetyl K280-tau-targeting monoclonal antibody for Alzheimer's disease
- Joint development agreement with Adel, Inc. in 2020
- Initiated P1 study in the US in 2023

- Current Status

- Completed P1a single-ascending dose part in healthy volunteers; data to be presented in CTAD 2025
- P1b multiple-ascending dose part in early AD patients underway
- Protocol amendment to include prescreening (pTau 217) and dosing adjustment (q4w)

- Prospect

- Potential licensing agreement with a global pharma before P2



Confidential

OCT-598

- History


- An EP2/4 dual antagonist, anticipated to help overcome cancer therapy resistance and immune evasion
- In-licensed from Kanaph Therapeutics in 2022
- Preclinical data presented at AACR 2023 and 2025

- Current Status

- IND approved by FDA (June) and MFDS (November)
- First-in-human dosing to start in December

- Prospect

- P1b docetaxel combination to start in mid-2026 in multiple solid tumor types; a second combination regimen planned to start in-late 2026 (CRC or SCLC)
- Trailblazing the development path for CTR programs to follow




Confidential

Vision 2030

- The inventor, pioneer, and champion of “**anti-cancer-anti-resistance therapy**”
- The number one ‘**first-in-class**’ drug discovery company in Korea
- Global reputation for;
 - Innovative pipeline
 - Breakthrough clinical results
 - **Multiple high-profile partnership deals**

History to Repeat Itself





Translating Science into Medicine

